Third Arc Bio Funding: $165M Raised, Series A (2024)
Third Arc Bio is a Biotech company based in Boston. It has raised $165M in total funding. Latest round: Series A.
Third Arc Bio funding overview
Third Arc Bio is a Biotech company based in Boston. Third Arc Bio has raised $165M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in July 2024. The round record for Third Arc Bio runs through 2024; nothing later has been disclosed. Investors on record include Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs Alternatives, BVF Partners LP and 8 others. 14 distinct backers are named across the disclosed rounds.
Third Arc Bio has raised $165M in total disclosed funding across the rounds on record.
Who has invested in Third Arc Bio?
Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs Alternatives, BVF Partners LP are named among the investors backing Third Arc Bio.
What was the latest Third Arc Bio funding round?
The most recent disclosed round is a Series A, announced in July 2024.
Where is Third Arc Bio based?
Third Arc Bio is based in Boston.
What sector does Third Arc Bio operate in?
Third Arc Bio is tracked under Biotech from Boston, with $165M in disclosed funding.
When did Third Arc Bio last raise?
The last disclosed Third Arc Bio round closed in July 2024 at Series A.
Round data for Third Arc Bio is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies in Boston and backer lists below.
